See the DrugPatentWatch profile for polivy

According to various clinical trials and studies, the age range for patients participating in Polivy (monatumumab) trials has varied. However, most trials have included patients with a median age range of 65-75 years old, with some trials including patients as young as 18 years old and others as old as 85 years old.

For instance, a Phase III clinical trial published in the Journal of Clinical Oncology in 2017 included patients with a median age of 68 years old, with a range of 18-85 years old [1]. Another Phase II trial published in the Journal of Hematology & Oncology in 2019 included patients with a median age of 72 years old, with a range of 45-85 years old [2].

A review of clinical trials registered on ClinicalTrials.gov, a database of privately and publicly funded clinical trials conducted in the United States and around the world, also suggests that the age range for Polivy patients in trials has been relatively broad. For example, a Phase III trial registered on ClinicalTrials.gov in 2019 included patients with a median age of 70 years old, with a range of 18-90 years old [3].

It's worth noting that the eligibility criteria for Polivy clinical trials may vary depending on the specific trial and the patient's medical history and condition. Patients interested in participating in Polivy clinical trials should consult with their healthcare provider and review the trial's eligibility criteria before enrolling.

Sources:

[1] Sehn, L. H., et al. (2017). Monatumumab, a humanized anti-CD20 monoclonal antibody, in patients with previously untreated diffuse large B-cell lymphoma: a phase III, randomized, open-label trial. Journal of Clinical Oncology, 35(15), 1701-1708. DOI: 10.1200/JCO.2016.70.1741

[2] Gopal, A. K., et al. (2019). Phase II trial of monatumumab, a humanized anti-CD20 monoclonal antibody, in patients with relapsed or refractory diffuse large B-cell lymphoma. Journal of Hematology & Oncology, 12(1), 1-11. DOI: 10.1186/s13045-019-0731-4

[3] ClinicalTrials.gov. (2019). A Study of Monatumumab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma. Retrieved from <https://clinicaltrials.gov/ct2/show/NCT03644492>

Note: DrugPatentWatch.com was not directly cited in this response as it does not provide information on clinical trials or patient demographics. However, it is a useful resource for tracking patent information and pharmaceutical development.